Vera Therapeutics To Present Multiple Presentations At American Society Of Nephrology Kidney Week 2026 For Its Final Efficacy Analysis Of ORIGIN 3 Study Of TRUTAKNA In IgA Nephropathy
Vera Therapeutics, Inc. (NASDAQ:VERA), a commercial-stage biotechnology company, today announced that there will be multiple presentations at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver,
Vera Therapeutics will show final results of its kidney disease medicine at a big conference next year. This is a chance to see if their drug actually works and what doctors think about it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.